Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 723682, 11 pages
http://dx.doi.org/10.1155/2015/723682
Research Article

Incidence and Prognostic Impact of DNMT3A Mutations in Korean Normal Karyotype Acute Myeloid Leukemia Patients

1Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-739, Republic of Korea
2Biomedical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-739, Republic of Korea
3Department of Laboratory Medicine, Hanmaeum Hospital, 21 Woni-daero, 682 Beon-gil, Seongsan-gu, Changwon-si, Gyeongsangnam-do 642-832, Republic of Korea
4Department of Laboratory Medicine, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 614-735, Republic of Korea
5Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Yangsan Hospital, 20 Geumo-ro, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do 626-770, Republic of Korea
6Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-739, Republic of Korea

Received 10 October 2014; Revised 22 December 2014; Accepted 22 December 2014

Academic Editor: Martin Bornhaeuser

Copyright © 2015 Sang Hyuk Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Byrd, K. Mrózek, R. K. Dodge et al., “Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461),” Blood, vol. 100, no. 13, pp. 4325–4336, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. D. Grimwade, H. Walker, F. Oliver et al., “The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties,” Blood, vol. 92, pp. 2322–2333, 1998. View at Google Scholar
  3. M. R. O'Donnell, C. N. Abboud, J. Altman et al., “Acute myeloid leukemia,” Journal of the National Comprehensive Cancer Network, vol. 10, no. 8, pp. 984–1021, 2012. View at Google Scholar · View at Scopus
  4. S. P. Whitman, K. J. Archer, L. Feng et al., “Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study,” Cancer Research, vol. 61, no. 19, pp. 7233–7239, 2001. View at Google Scholar · View at Scopus
  5. Y. Yamamoto, H. Kiyoi, Y. Nakano et al., “Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies,” Blood, vol. 97, no. 8, pp. 2434–2439, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Kainz, D. Heintel, R. Marculescu et al., “Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16),” The Hematology Journal, vol. 3, no. 6, pp. 283–289, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. S. P. Whitman, K. Maharry, M. D. Radmacher et al., “FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study,” Blood, vol. 116, no. 18, pp. 3622–3626, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. S. P. Whitman, A. S. Ruppert, M. D. Radmacher et al., “FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications,” Blood, vol. 111, no. 3, pp. 1552–1559, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. S. Schnittger, C. Schoch, W. Kern et al., “Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype,” Blood, vol. 106, no. 12, pp. 3733–3739, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. K. Döhner, R. F. Schlenk, M. Habdank et al., “Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations,” Blood, vol. 106, no. 12, pp. 3740–3746, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. G. W. Verhaak, C. S. Goudswaard, W. van Putten et al., “Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance,” Blood, vol. 106, no. 12, pp. 3747–3754, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. Fröhling, R. F. Schlenk, I. Stolze et al., “CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations,” Journal of Clinical Oncology, vol. 22, no. 4, pp. 624–633, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. C. L. Green, K. K. Koo, R. K. Hills, A. K. Burnett, D. C. Linch, and R. E. Gale, “Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations,” Journal of Clinical Oncology, vol. 28, no. 16, pp. 2739–2747, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. C. Preudhomme, C. Sagot, N. Boissel et al., “Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA),” Blood, vol. 100, no. 8, pp. 2717–2723, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. S. H. Park, H. S. Chi, Y. U. Cho, S. Jang, and C. J. Park, “CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk,” Leukemia Research, vol. 37, no. 11, pp. 1488–1494, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. S. Abbas, S. Lugthart, F. G. Kavelaars et al., “Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value,” Blood, vol. 116, no. 12, pp. 2122–2126, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. P. Paschka, R. F. Schlenk, V. I. Gaidzik et al., “IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication,” Journal of Clinical Oncology, vol. 28, no. 22, pp. 3636–3643, 2010. View at Publisher · View at Google Scholar · View at PubMed
  18. H.-Y. Chao, Z.-X. Jia, T. Chen et al., “IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype,” International Journal of Laboratory Hematology, vol. 34, no. 5, pp. 502–509, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. F. Ravandi, K. Patel, R. Luthra et al., “Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin,” Cancer, vol. 118, no. 10, pp. 2665–2673, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. J. Ley, L. Ding, M. J. Walter et al., “DNMT3A mutations in acute myeloid leukemia,” The New England Journal of Medicine, vol. 363, no. 25, pp. 2424–2433, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. X.-J. Yan, J. Xu, Z.-H. Gu et al., “Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia,” Nature Genetics, vol. 43, no. 4, pp. 309–315, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. M. A. McDevitt, “Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies,” Seminars in Oncology, vol. 39, no. 1, pp. 109–122, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. J. Trowbridge, J. W. Snow, J. Kim, and S. H. Orkin, “DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells,” Cell Stem Cell, vol. 5, no. 4, pp. 442–449, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. F. Thol, F. Damm, A. Lüdeking et al., “Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia,” Journal of Clinical Oncology, vol. 29, no. 21, pp. 2889–2896, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. A. Renneville, N. Boissel, O. Nibourel et al., “Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association,” Leukemia, vol. 26, no. 6, pp. 1247–1254, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. G. Marcucci, K. H. Metzeler, S. Schwind et al., “Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia,” Journal of Clinical Oncology, vol. 30, no. 7, pp. 742–750, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. J. Markova, P. Michkova, K. Burckova et al., “Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia,” European Journal of Haematology, vol. 88, no. 2, pp. 128–135, 2012. View at Publisher · View at Google Scholar · View at PubMed
  28. Y. Shen, Y. M. Zhu, X. Fan et al., “Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia,” Blood, vol. 118, no. 20, pp. 5593–5603, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. H.-A. Hou, Y.-Y. Kuo, C.-Y. Liu et al., “DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications,” Blood, vol. 119, no. 2, pp. 559–568, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. Y. Wang, L. Y. Geer, C. Chappey, J. A. Kans, and S. H. Bryant, “Cn3D: sequence and structure views for Entrez,” Trends in Biochemical Sciences, vol. 25, no. 6, pp. 300–302, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. M. S. Kim, Y. R. Kim, N. J. Yoo, and S. H. Lee, “Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers,” APMIS, vol. 121, no. 2, pp. 85–94, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus